1. Home
  2. SCYX

as 12-24-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Founded: 1999 Country:
United States
United States
Employees: N/A City: JERSEY CITY
Market Cap: 50.3M IPO Year: 2014
Target Price: N/A AVG Volume (30 days): 212.5K
Analyst Decision: Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.78 EPS Growth: N/A
52 Week Low/High: $0.90 - $3.07 Next Earning Date: 11-06-2024
Revenue: $8,566,000 Revenue Growth: -93.70%
Revenue Growth (this year): -92.42% Revenue Growth (next year): 405.82%

SCYX Daily Stock ML Predictions

Share on Social Networks: